Curcumenol, a
sesquiterpene isolated from Curcuma zedoaria is known to possess a variety of health and medicinal values which includes neuroprotection, anti-inflammatory, anti-
tumor and hepatoprotective activities. The current study aim is to investigate the modulatory effects of
curcumenol towards the
lipopolysaccharides (LPS)-induced
inflammation in BV-2 microglia.
Curcumenol markedly decreased LPS-induced production of
nitric oxide (NO), pro-inflammatory
cytokines [(IL-6) and (TNF-α)] and pro-inflammatory
proteins expression, iNOS and COX-2. Moreover,
curcumenol inhibited NF-κB activation by suppressing the nuclear translocation of the NF-κB p65 subunit and blocking IκBα phosphorylation and degradation. Furthermore, an NF-κB inhibitor, ethyl 3,4-dihydroxycinnamate also known as
caffeic acid ethyl ester (CAEE), attenuated LPS-stimulated iNOS and COX-2 expression, suggesting that NF-κB inhibition is a regulator in the expression of iNOS and COX-2
proteins. Further mechanistic study with an Akt inhibitor,
triciribine hydrate (API-2), revealed that
curcumenol acted through Akt-dependent NF-κB activation. Moreover,
curcumenol inhibition on LPS-induced phosphorylation of
p38 MAPK is confirmed by its inhibitor (
SB 202190). These results indicate that
curcumenol diminishes the proinflammatory mediators and the expression of the regulatory genes in LPS-stimulated BV-2 by inhibiting Akt-dependent NF-κB activation and downregulation of Akt and p38 MAPKs signaling.